JNJ

227.84

+1.49%↑

ISRG

522.43

-0.51%↓

ABT

105.93

-2.09%↓

MDT

100.66

-0.05%↓

A

133.89

-1.33%↓

JNJ

227.84

+1.49%↑

ISRG

522.43

-0.51%↓

ABT

105.93

-2.09%↓

MDT

100.66

-0.05%↓

A

133.89

-1.33%↓

JNJ

227.84

+1.49%↑

ISRG

522.43

-0.51%↓

ABT

105.93

-2.09%↓

MDT

100.66

-0.05%↓

A

133.89

-1.33%↓

JNJ

227.84

+1.49%↑

ISRG

522.43

-0.51%↓

ABT

105.93

-2.09%↓

MDT

100.66

-0.05%↓

A

133.89

-1.33%↓

JNJ

227.84

+1.49%↑

ISRG

522.43

-0.51%↓

ABT

105.93

-2.09%↓

MDT

100.66

-0.05%↓

A

133.89

-1.33%↓

Search

Cartesian Therapeutics Inc

Chiusa

7.23 -1.36

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

7.09

Massimo

7.41

Raccomandazioni

By TipRanks

Raccomandazioni

Fortemente da comprare

Previsioni per 12 mesi

+359.92% upside

Dividendi

By Dow Jones

Utili prossimi

11 mar 2026

Cartesian Therapeutics Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

27 gen 2026, 23:07 UTC

Utili

Texas Instruments Says Data Centers, Industrial Recovery Driving Growth into 1Q -- Update

27 gen 2026, 21:27 UTC

Utili

Texas Instruments 4Q Sales Rise, Profit Falls

27 gen 2026, 23:55 UTC

Discorsi di Mercato

Yen Weakens Slightly on Possible Technical Correction -- Market Talk

27 gen 2026, 23:47 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

27 gen 2026, 23:47 UTC

Discorsi di Mercato

Nikkei May Decline Amid Caution Over Earnings -- Market Talk

27 gen 2026, 23:39 UTC

Discorsi di Mercato

Gold Falls on Likely Technical Correction, Possible Profit-Taking -- Market Talk

27 gen 2026, 23:20 UTC

Utili

SK Innovation: Asset-Impairment Losses Weighed on Earnings

27 gen 2026, 23:20 UTC

Utili

SK Innovation: Industry Downturn, Narrower Profit Margins Weighed on Earnings

27 gen 2026, 23:19 UTC

Utili

SK Innovation Posts Net Loss for Second Consecutive Year

27 gen 2026, 23:19 UTC

Utili

SK Innovation 2025 Loss KRW5.406T Vs. Loss KRW2.372T >096770.SE

27 gen 2026, 23:18 UTC

Utili

SK Innovation 2025 Oper Pft KRW448.07B Vs. Pft KRW356.07B >096770.SE

27 gen 2026, 23:18 UTC

Utili

SK Innovation 2025 Rev KRW80.296T Vs. KRW74.243T >096770.SE

27 gen 2026, 23:11 UTC

Discorsi di Mercato

Global Equities Roundup: Market Talk

27 gen 2026, 23:11 UTC

Discorsi di Mercato

Alkane Resources Bull Positive on Outlook in Red-Hot Gold Market -- Market Talk

27 gen 2026, 23:07 UTC

Discorsi di Mercato
Acquisizioni, Fusioni, Takeovers

Freightways's Australian M&A Adds Ballast to Bull's View -- Market Talk

27 gen 2026, 22:17 UTC

Discorsi di Mercato

U.S. Dollar Slips Following Trump Comments -- Market Talk

27 gen 2026, 22:06 UTC

Utili

Boeing's Stepped-Up Plane Deliveries Lift Sales -- Update

27 gen 2026, 21:51 UTC

Utili

Texas Instruments Stock Jumps on Strong Outlook -- Barrons.com

27 gen 2026, 21:50 UTC

Discorsi di Mercato

Basic Materials Roundup: Market Talk

27 gen 2026, 21:43 UTC

Utili

RTX Stock Jumps After Earnings. It Has 'Great Momentum,' Says CEO. -- Barrons.com

27 gen 2026, 21:41 UTC

Utili

GM Lost Billions on EVs, Still Beat Wall Street's Expectations -- 5th Update

27 gen 2026, 21:38 UTC

Utili

These Stocks Are Today's Movers: UnitedHealth, Humana, Micron, Corning, CoreWeave, UPS, GM, and More -- Barrons.com

27 gen 2026, 21:32 UTC

Utili

Ampol: Modest Profit From F&I International in 2025

27 gen 2026, 21:32 UTC

Utili

Ampol: F&I Australia Ebit Up by High Single Digit Percent in 2025

27 gen 2026, 21:31 UTC

Utili

Ampol: New Zealand Ebit in 2025 In Line With Prior Year

27 gen 2026, 21:31 UTC

Utili

Ampol: Australia Convenience Retail Ebit Up Mid-Single Digit Percent in 2025

27 gen 2026, 21:30 UTC

Utili

Ampol 4Q Lytton Refinery Production 1.56 Billion Liters

27 gen 2026, 21:29 UTC

Utili

Ampol FY Unaudited Replacement-Cost Ebitda A$1.44 Billion

27 gen 2026, 21:29 UTC

Utili

Ampol FY Unaudited Replacement-Cost Operating Profit A$945 Million

27 gen 2026, 21:28 UTC

Utili

Ampol 4Q Lytton Refiner Margin US$15.14/Bbl

Confronto tra pari

Modifica del prezzo

Cartesian Therapeutics Inc Previsione

Obiettivo di Prezzo

By TipRanks

359.92% in crescita

Previsioni per 12 mesi

Media 35 USD  359.92%

Alto 44 USD

Basso 16 USD

Basato su 8 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Cartesian Therapeutics Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

8 ratings

6

Acquista

2

Mantieni

0

Vendi

Notizie finanziarie

$

help-icon Live chat